Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening

Aleman, Michael; Karakiewicz, Pierre I.; Kupelian, Patrick A.; Kattan, Michael W.; Graefen, Markus; Cagiannos, Ilias; Eastham, James A.; Scardino, Peter T.; Huland, Hartwig; Klein, Eric A.

doi:10.1016/s0090-4295(03)00125-0

Cited by 38 publications

(17 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…but rather, "What value/information does the biomarker add to the existing clinical data?" Even "standalone" biomarkers such as prostate-specific antigen or troponin are more accurate when combined with clinical data such as age (55) or combined with other biomarkers (56). Biomarker combinations may enhance the sensitivity and specificity over each individual biomarker (Figure 4).…”

Section: : Combining Biomarker With Clinical Data and Other Biomarkersmentioning

confidence: 99%

Discovery of Protein Biomarkers for Renal Diseases

Hewitt¹,

Dear²,

Star³

2004

Journal of the American Society of Nephrology

272

150

View full text Add to dashboard Cite

Abstract. Animal models and human studies have been useful in dissecting the molecular mechanisms of renal disease and finding new disease targets; however, translation of these findings to new clinical therapeutics remains challenging. Difficulties with detecting early disease, measuring drug effectiveness, and the daunting cost of clinical trials hampers the development of new therapeutics for renal diseases. Many existing laboratory tests were discovered because of inspired recognition that a particular protein might prove useful in clinical practice. New unbiased genomic and proteomic techniques identify many constituents present in biologic samples and thus may greatly accelerate biomarker research. This review focuses on the steps needed to develop new biomarkers that are useful in laboratory and clinical investigations, with particular focus on new proteomic screening technologies. New biomarkers will speed the laboratory and clinical development of new treatments for renal diseases through mechanistic insights, diagnoses that are more refined, early detection, and enhanced proof of concept testing.

show abstract

Section: : Combining Biomarker With Clinical Data and Other Biomarkersmentioning

confidence: 99%

Discovery of Protein Biomarkers for Renal Diseases

Hewitt¹,

Dear²,

Star³

2004

Journal of the American Society of Nephrology

272

150

View full text Add to dashboard Cite

show abstract

“…Poor prognosis is reported with advanced age. [23,24] However, some studies did not find any effect at all. [25,26] In another meta-analysis study, age was not found to be a prognostic factor.…”

Section: Discussionmentioning

confidence: 99%

Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy

Ün¹,

Türk²,

Koca³

et al. 2015

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: This study was conducted to research the factors determining biochemical recurrence (BCR) in low-risk localized prostate cancer patients who underwent radical prostatectomy (RP). Material and methods:We retrospectively analyzed the data of 504 patients who had undergone RP between 2003 and 2013 at our clinic. One hundred and fifty-two patients who underwent RP for low-risk prostate cancer were included in the study. Results:The mean follow-up period for patients was 58.7 (21-229) months. The mean age of the patients was 63.7±7.2 years (49-79). The mean prostate specific antigen (PSA) value was 5.25±4.22 ng/mL (3.58-9.45). The BCR rate after the operation was 25% (38/152). In the univariate analysis, recurrence determining factors were shown to include extracapsular involvement (ECI) (p= 0.004), capsular invasion (CI) (p= 0.001), age (p= 0.014), and tumor size (p= 0.006). However, only CI was found to be significant in multivariate analysis (p= 0.001). Conclusion:Capsular invasion is an independent risk factor in low-risk prostate cancer patients who underwent RP for BCR.

show abstract

“…Therefore, rather than tumor volume, a better end point is the biological potential of the cancer. When this type of analysis has been performed using biochemical progression as a substitute end point, some [10,11] , but not all studies [12] have found that lower PSA values were associated with better outcomes in men with a PSA less than 10 ng/ ml.…”

Section: Discussionmentioning

confidence: 99%